- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00019591
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
A Phase I/II Trial of Vaccination With Mutant Ras Peptide-Pulsed Dendritic Cells in the Treatment of HLA A2.1 Positive Patients With Colorectal Cancer
RATIONALE: Vaccines may make the body build an immune response that will kill cancer cells. Combining vaccine therapy with interleukin-2 may kill more cancer cells.
PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have locally advanced or metastatic colorectal cancer.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
- Determine the frequency of immunologic response in patients with locally advanced or metastatic colorectal cancer treated with ras peptide-pulsed dendritic cell vaccine with or without interleukin-2.
- Determine the tumor response and survival time in patients with metastatic colorectal cancer treated with vaccine plus interleukin-2.
- Determine the time to progression in patients with locally advanced colorectal cancer treated with adjuvant vaccine.
OUTLINE: Patients are assigned to 1 of 2 treatment groups according to extent of disease. Patients with prior locally advanced disease are assigned to treatment group A, while those with metastatic disease are assigned to treatment group B.
- Group A: Patients are vaccinated against influenza on day -6. Patients undergo collection of peripheral blood mononuclear cells (PBMC) on day -4. The PBMC are cultured with sargramostim (GM-CSF) and interleukin-4 for 5 days and CD40 ligand for 24 hours and then pulsed for 2 hours with the appropriate peptide to form a vaccine. Patients receive ras peptide-pulsed dendritic cell vaccine IV over 5 minutes on days 1, 15, 29, 43, and 57.
- Group B: Patients undergo collection of PBMC and receive vaccination as in group A. Patients also receive interleukin-2 subcutaneously on days 2-6 and 9-13.
Treatment in both groups repeats every 2 weeks for up to 5 vaccinations in the absence of disease progression or unacceptable toxicity.
Patients are followed on days 75, 90, 120, and 365.
PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study within 3 years.
Tipo de estudo
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232-6838
- Vanderbilt-Ingram Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
- Histologically confirmed locally advanced or metastatic colorectal cancer
- Metastatic disease must be radiologically proven
- HLA-A2-1 positive
- Locally advanced disease must have had prior resection or incomplete resection with poor prognosis
Locally advanced disease includes:
- Stage III or IV colon cancer (T4 or any T, N2-3, M0)
- Stage III or IV rectal cancer (T4 or T3, N1-3)
- Resectable or unresectable T4 disease after radiotherapy, chemotherapy, and/or surgery
- Absence of measurable disease but more than a 50% chance of recurrence
- Completely resected or locally advanced disease may have had conventional therapy completed within 1-12 months (surgery alone, with or without adjuvant chemotherapy and/or radiotherapy) prior to study entry
Metastatic disease patients must have bidimensionally measurable disease
- Bone lesions with well-demarcated borders allowed
- Lesions seen only on bone scan, pleural effusions, ascites, and changes in carcinoembryonic antigen are not considered measurable disease
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- ECOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- Lymphocyte count at least 470/mm^3
- Granulocyte count at least 1,000/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 2.0 mg/dL*
- SGOT no greater than 4 times upper limit of normal (ULN) (2.5 times ULN for adjuvant patients)*
- Albumin at least 3 g/dL
- No active viral hepatitis
- No evidence of chronic infection due to hepatitis C
- Hepatitis B surface antigen negative NOTE: *Unless due to metastatic disease
Renal:
- Creatinine no greater than 2.0 mg/dL
Cardiovascular:
- No history of cardiac failure, significant arrhythmias, or coronary artery disease (metastatic disease patients only)
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception
- HIV negative
- No prior malignancy with a 50% chance of recurrence within 5 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix
- No medical or psychiatric condition that would preclude compliance
- No serious medical condition that would preclude apheresis
- No serious infection
- No uncontrolled thyroid disease (metastatic disease patients only)
- Patients with an allergy to eggs are allowed but are not vaccinated against influenza during study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior immunologic therapy directed at the cellular immune system
Chemotherapy:
- See Disease Characteristics
- Prior chemotherapy for metastatic disease allowed
- At least 4 weeks since prior chemotherapy
- No concurrent chemotherapy or anticipated need for chemotherapy for 2 months after vaccinations
Endocrine therapy:
- At least 4 weeks since prior supraphysiologic steroid therapy
Radiotherapy:
- See Disease Characteristics
- Prior radiotherapy for metastatic disease allowed
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
- Prior surgery for metastatic disease allowed
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
---|
Response rate every 3 months for up to a year after completion of study treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: John E. Janik, MD, NCI - Metabolism Branch;MET
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Neoplasias
- Neoplasias por local
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças Gastrointestinais
- Doenças do cólon
- Doenças Intestinais
- Neoplasias Intestinais
- Doenças retais
- Neoplasias Colorretais
- Agentes Anti-Infecciosos
- Antivirais
- Agentes anti-HIV
- Antirretrovirais
- Agentes Antineoplásicos
- Aldesleucina
Outros números de identificação do estudo
- CDR0000066874
- NCI-99-C-0023L
- NCI-T98-0034
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer colorretal
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos